Progress on application of dipeptidyl peptidase Ⅲ in the treatment of sepsis

doi:10.16352/j.issn.1001-6325.2023.01.0196

Abstract

Abstract: Sepsis is still one of the important challenges of medicine in the 21st century. Dipeptide peptidase Ⅲ(DPP3)is a new biomarker associated with sepsis, which mainly degrades angiotensin Ⅱ in human body. It can not only inhibit cardiac systolic function, but also reduce vascular tension, resulting in insufficient cardiac output and low blood pressure, resulting in shock and multiple organ dysfunctions in patients with sepsis. Therefore, DPP3 may become a new target for sepsis treatment.

Key words: sepsis, septic shock, dipeptidyl peptidase Ⅲ(DPP3), heart failure

CLC Number:

R459.7

WANG Yingchen, SUN Liqun. Progress on application of dipeptidyl peptidase Ⅲ in the treatment of sepsis[J]. Basic & Clinical Medicine, 2023, 43(1): 196-199.

References

[1] Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315: 801-810.
[2] Kyriazopoulou E, Liaskou-Anyoniou L, Adamis G, et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis. a randomized trial[J]. Am J Respir Crit Care Med, 2021, 203: 202-210.
[3] Peng F, Chang W, Xie JF, et al. Ineffectiveness of procalcitonin-guided antibiotic therapy in severely critically ill patients: a meta-analysis[J]. Int J Infect Dis, 2019, 85: 158-166.
[4] 文大林,杜娟,陈民佳, 等. 联合检测C反应蛋白和降钙素原在创伤后脓毒症患者早期预警中的作用[J]. 基础医学与临床, 2020, 40: 178-181.
[5] Sabljić I, Meštrović N, Vukelić B, et al. Crystal structure of. dipeptidyl peptidase Ⅲ from the human gut symbiont bacteroides thetaiotaomicron[J]. PLoS One, 2017, 12: e0187295. doi: 10.1371/journal.pone.0187295.
[6] Menale C, Robinson LJ, Palagano E, et al. Absence of dipeptidyl peptidase 3 increases oxidative stress and causes bone loss[J]. J Bone Miner Res, 2019, 34: 2133-2148.
[7] Jha S, Taschler U, Domenig O, et al. Dipeptidyl pepti-dase 3 modulates the renin-angiotensin system in mice[J]. J Biol Chem, 2020, 295: 13711-13723.
[8] Cruz-Diaz N, Wilson BA, Pirro NT, et al. Identification of dipeptidyl peptidase 3 as the angiotensin-(1-7) degrading peptidase in human HK-2 renal epithelial cells[J]. Peptides, 2016, 83: 29-37.
[9] Komeno M, Pang X, Shimizu A, et al. Cardio- and reno-protective. effects of dipeptidyl peptidase Ⅲ in diabetic mice[J]. J Biol Chem, 2021, 296: 100761. doi: 10.1016/j.jbc.2021.100761.
[10] Lu K, Alcivar AL, Ma J, et al. NRF2 induction support-ing breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP1 interaction[J]. Cancer Res, 2017, 77: 2881-2892.
[11] Takagi K, Blet A, Levy B, et al. Circulating dipeptidyl peptidase 3 and alteration in haemodynamics in cardiogenic shock: results from the OptimaCC trial[J]. Eur J Heart Fail, 2020, 22: 279-286.
[12] Deniau B, Rehfeld L, Santos K, et al. Circulating dipeptidyl peptidase 3 is a myocardial depressant factor: dipeptidyl peptidase 3 inhibition rapidly and sustainably improves haemodynamics[J]. Eur J Heart Fail, 2020, 22: 290-299.
[13] Rehfeld L, Funk E, Jha S, et al. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples[J]. J Appl Lab Med, 2019, 3: 943-953.
[14] Dépret F, Amzallag J, Pollina A, et al. Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients[J]. Crit Care, 2020, 24: 168. doi: 10.1186/s13054-020-02888-5.
[15] Bitker L, Burrell LM. Classic and nonclassic renin-angiotensin systems in the critically ill[J]. Crit Care Clin, 2019, 35: 213-227.
[16] Deniau B, Blet A, Santos K, et al. Inhibition of circulating. dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: a proof of concept study[J]. PLoS One, 2020, 15: e0238039. doi: 10.1371/journal.pone.0238039.
[17] Blet A, Deniau B, Santos K, et al. Monitoring circulat-ing. dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study[J]. Crit Care, 2021, 25: 61. doi: 10.1186/s13054-021-03471-2.
[18] Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med, 2021, 47: 1181-1247.
[19] 曹钰,柴艳芬,邓颖, 等. 中国脓毒症/脓毒性休克急诊治疗指南(2018)[J]. 临床急诊杂志, 2019, 20: 3-22.
[20] Lamontagne F, Richards-Belle A, Thomas K, et al. Effect of reduced exposure to vasopressors on 90-Day mortality in older critically ill patients with vasodilatory hypotension: a randomized clinical trial[J]. Jama, 2020, 323: 938-949.
[21] 利军保. 去甲肾上腺素对重症脓毒性休克患者肾功能及血流动力学的影响[J]. 临床医学研究与实践, 2020, 5: 57-58.
[22] Permpikul C, Tongyoo S, Viarasilpa T, et al. Early Use of norepinephrine in septic shock resuscitation (CENSER). a randomized trial[J]. Am J Respir Crit Care Med, 2019, 199: 1097-1105.
[23] Mebazza A, Motiejunaite J, Gayat E, et al. Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry[J]. Eur J Heart Fail, 2018, 20: 332-341.
[24] Harhay MO, Casey JD, Clement M, et al. Contemporary strategies to improve clinical trial design for critical care research: insights from the First Critical Care Clinical Trialists Workshop[J]. Intensive Care Med, 2020, 46: 930-942.